CHRS Overview
Upcoming Projects (CHRS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CHRS)
-
Examining Coherus' Toripalimab in Nasopharyngeal Carcinoma before the April 29th PDUFA
Ticker: CHRS
Executed On: Apr 26, 2022 at 02:30 PM EDT -
A look at the upcoming PDUFA of Toripalimab and the potential in nasopharyngeal carcinoma (NPC).
Ticker: CHRS
Executed On: Mar 18, 2022 at 02:00 PM EDT
Expired Projects (CHRS)
-
Comparing Coherus' Cimerli anti-VEGF with Lucentis in treating Wet AMD
Tickers: CHRS, RHHBY
Execute By: Sep 08, 2022
Upcoming & Overdue Catalysts (CHRS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CHRS)
-
Coherus has indicated that it expects to file its CHS-1701 Biologics License Application (BLA) in the second quarter of 2016
Ticker: CHRS
Occurred on: Aug 09, 2016 -
Phase 3 data of CHS-0214 for Rheumatoid arthritis due 1Q 2016
Ticker: CHRS
Occurred on: Jun 10, 2016
Strategic Initiatives (CHRS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!